<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04941261</url>
  </required_header>
  <id_info>
    <org_study_id>CXSL1700011-Ⅱ</org_study_id>
    <nct_id>NCT04941261</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenula Polymorpha)</brief_title>
  <official_title>Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine(Hansenula Polymorpha) in Healthy People Aged Aged From 6 Months to 59 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Vaccine and Serum Institute, China</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lanzhou Institute of Biological Products Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Zhong Sheng Heng Yi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Vaccine and Serum Institute, China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II clinical study will explore dose and safety, immunogenicity in 4 age groups,&#xD;
      including 18-59 years old group, 6-17 years old group, 3-5 years old group, 6-35 months old&#xD;
      group, with a total of 1716 subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the incidence and severity of any adverse reactions/events within 30 minutes after each dose of vaccination</measure>
    <time_frame>through 30 minutes after each dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>the incidence and severity of adverse reactions/events within 0-7 days after each dose of vaccination</measure>
    <time_frame>through 7 days after each dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>the incidence and severity of non-collective adverse reactions/events within 30 days after each dose of vaccination</measure>
    <time_frame>through 30 days after each dose</time_frame>
    <description>If there is still next vaccination ，collect the incidence and severity of non-collective adverse reactions/events within vaccination interval（28 days） after vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the incidence of SAE from the first dose of vaccination to 6 months after the full course of vaccination</measure>
    <time_frame>up to 6 months after the full course of vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody titer of HBGA-blocking antibody on the 14th day after the full course of vaccination</measure>
    <time_frame>14th day after the full course of vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>4-fold Seroconversion rate on the 14th day after the full course of vaccination</measure>
    <time_frame>14th day after the full course of vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody titer of（NoV GI.1 and GII.4 HBGA-blocking antibody）on the 14th day after the full course of vaccination</measure>
    <time_frame>14th day after the full course of vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric mean Titer of（NoV GI.1 and GII.4 HBGA-blocking antibody）on the 14th day after the full course of vaccination</measure>
    <time_frame>14th day after the full course of vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune response（compared with before vaccination, the antibody increased by 4 times or more） rate of（NoV GI.1 and GII.4 HBGA-blocking antibody）on the 14th day after the full course of vaccination</measure>
    <time_frame>14th day after the full course of vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody titer of（NoV GI.1 and GII.4 HBGA-blocking antibody）on 90th,180th,270th,360th,540th,720th day after the full course of vaccination</measure>
    <time_frame>90th,180th,270th,360th,540th,720th day after the full course of vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binding Antibody (IgG) on 90th,180th,270th,360th,540th,720th day after the full course of vaccination</measure>
    <time_frame>90th,180th,270th,360th,540th,720th day after the full course of vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>15</number_of_arms>
  <enrollment type="Anticipated">1716</enrollment>
  <condition>Norovirus Infections</condition>
  <condition>Norwalk Gastroenteritis</condition>
  <arm_group>
    <arm_group_label>18-59 years old group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>18-59 years old group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>18-59 years old group C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>6-17 years old group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>6-17 years old group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>6-17 years old group C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3-5 years old group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3-5 years old group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3-5 years old group C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>6-35 months old group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>6-35 months old group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>6-35 months old group C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>6-35 months old group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>6-35 months old group E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>6-35 months old group F</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>low-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine</intervention_name>
    <description>Intramuscular injection of low-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine in the deltoid muscle of the upper arm</description>
    <arm_group_label>18-59 years old group A</arm_group_label>
    <arm_group_label>3-5 years old group A</arm_group_label>
    <arm_group_label>6-17 years old group A</arm_group_label>
    <arm_group_label>6-35 months old group A</arm_group_label>
    <arm_group_label>6-35 months old group D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>high-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine</intervention_name>
    <description>Intramuscular injection of high-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine in the deltoid muscle of the upper arm</description>
    <arm_group_label>18-59 years old group B</arm_group_label>
    <arm_group_label>3-5 years old group B</arm_group_label>
    <arm_group_label>6-17 years old group B</arm_group_label>
    <arm_group_label>6-35 months old group B</arm_group_label>
    <arm_group_label>6-35 months old group E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Intramuscular injection of placebo in the deltoid muscle of the upper arm</description>
    <arm_group_label>18-59 years old group C</arm_group_label>
    <arm_group_label>3-5 years old group C</arm_group_label>
    <arm_group_label>6-17 years old group C</arm_group_label>
    <arm_group_label>6-35 months old group C</arm_group_label>
    <arm_group_label>6-35 months old group F</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age range: healthy people aged 6 months -59 years and and older who can provide legal&#xD;
             identification;&#xD;
&#xD;
          -  Inquired about medical history and physical examination, the investigator judged that&#xD;
             the health condition is good;&#xD;
&#xD;
          -  The subject and/or his legal guardian and/or his entrusted person can understand the&#xD;
             study procedures and informed consent, voluntarily sign informed consent form, and be&#xD;
             able to comply with the requirements of the clinical study protocol;&#xD;
&#xD;
          -  Females of childbearing age (menarche to menopause) are not pregnant at the time of&#xD;
             enrollment (negative urine pregnancy test), not breastfeeding, and have no birth plan&#xD;
             within 12 months after enrollment; effective contraception will be taken within 2&#xD;
             weeks before enrollment;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        First Dose Exclusion Criteria：&#xD;
&#xD;
          -  Axillary body temperature is not less than 37.3℃ (older than 14 years) before&#xD;
             vaccination, and axillary body temperature is not less than 37.5℃ (14 years or&#xD;
             younger) before vaccination;&#xD;
&#xD;
          -  Congenital malformations or developmental disorders, genetic defects, severe&#xD;
             malnutrition, etc;&#xD;
&#xD;
          -  Have received immune enhancement or inhibitor therapy within 3 months (continuous oral&#xD;
             or instillation for more than 14 days);&#xD;
&#xD;
          -  Have been diagnosed with congenital or acquired immunodeficiency, HIV infection,&#xD;
             lymphoma, leukemia or other autoimmune diseases;&#xD;
&#xD;
          -  Having serious congenital malformations or chronic diseases (including but not limited&#xD;
             to:Down syndrome, thalassemia, heart disease, kidney disease, diabetes, autoimmune&#xD;
             disease, genetic allergies, Guillain Barre syndrome, etc.);&#xD;
&#xD;
          -  Asthenia or splenectomy, functional asthenia caused by any situation;&#xD;
&#xD;
          -  Severe liver and kidney disease, severe cardiovascular disease, drug-uncontrollable&#xD;
             hypertension (systolic blood pressure is not less than 140mmHg, diastolic blood&#xD;
             pressure is not less than 90mmHg), high blood glucose, diabetic complications ,&#xD;
             Malignant tumors, various acute diseases or acute attacks of chronic diseases;&#xD;
&#xD;
          -  Have a history of chronic gastrointestinal disease, current diarrhea or other&#xD;
             digestive system diseases, gastroenteritis requiring treatment in the past 7 days;&#xD;
&#xD;
          -  Have a history of abnormal coagulation function (such as coagulation factor&#xD;
             deficiency, coagulopathy);&#xD;
&#xD;
          -  Have a history of severe allergic reactions to vaccination; allergic to any component&#xD;
             of the experimental vaccine&#xD;
&#xD;
          -  Have received a live attenuated vaccine within 28 days before vaccination, or received&#xD;
             other vaccines（Recombinant vaccine, subunit vaccine, inactivated vaccine） within 14&#xD;
             days before vaccination;&#xD;
&#xD;
          -  Received within 6 months before vaccination or plan to receive other study drugs in&#xD;
             the near future&#xD;
&#xD;
          -  Plan to move before the end of the study or leave the local area for a long time&#xD;
             during the scheduled study visit; Other conditions considered by the investigator to&#xD;
             be inappropriate for participation in the study.&#xD;
&#xD;
        In addition to the general exclusion criteria, specific populations should also follow the&#xD;
        following exclusion criteria:&#xD;
&#xD;
        -Children aged 24 months and under are born prematurely (delivered before the 37th week of&#xD;
        pregnancy), low-weight (birth weight for girls &lt;2300g, boys &lt;2500g) infants; Children 24&#xD;
        months of age and younger have a history of dystocia, birth asphyxia or other reasons, a&#xD;
        history of neurological damage, severe chronic diseases (such as Down syndrome, sickle cell&#xD;
        anemia, or neurological disorders).&#xD;
&#xD;
        Subsequent doses of vaccination Exclusion criteria：&#xD;
&#xD;
          -  Have a high fever (axillary temperature is not less than 39.0℃) for three days and&#xD;
             severe allergic reaction after the previous dose of vaccination;&#xD;
&#xD;
          -  Severe adverse reactions that are causally related to the previous dose of&#xD;
             vaccination;&#xD;
&#xD;
          -  For those newly discovered or newly identified after the previous dose of vaccine that&#xD;
             does not meet the first dose selection criteria or meets the first dose exclusion&#xD;
             criteria, the investigator will determine whether to continue participating in the&#xD;
             study;&#xD;
&#xD;
          -  Other exclusion reasons considered by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xia shengli, bachelor</last_name>
    <phone>（+86）13592610137</phone>
    <email>1792865518@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>qixian Center for Disease Control and Prevention</name>
      <address>
        <city>Hebi</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>dacheng zhan</last_name>
      <phone>15803925825</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 18, 2021</study_first_submitted>
  <study_first_submitted_qc>June 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2021</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caliciviridae Infections</mesh_term>
    <mesh_term>Gastroenteritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

